Pharmacological Challenges in Anxiety Disorders
Lawrence H. Price, Andrew W. Goddard, Linda C. Barr
Clinical Neuroscience Research Unit
Abraham Ribicoff Research Facilities
Connecticut Mental Health Center
Department of Psychiatry
Yale University School of Medicine
New Haven, Connecticut 06519.
Wayne K. Goodman
Department of Psychiatry
University of Florida College of Medicine
Gainesville, Florida 32610.
1. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991;48:157–162.
2. Abelson J, Nesse R. Cholecystokinin-4 and panic. Arch Gen Psychiatry 1990;47:395.
3. Albus M, Zahn TP, Breier A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur Arch Psychiatry Clin Neurosci 1992;241:337–344.
4. Albus M, Zahn TP, Breier A. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Eur Arch Psychiatry Clin Neurosci 1992;241:345–351.
5. Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:9–20.
6. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 1992;43:65–76.
7. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992;53[4, Suppl]:17–28.
8. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:309–317.
9. Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:833–839.
10. Benkelfat C, Murphy DL, Zohar J, et al. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry 1989;46:23–28.
11. Bradwejn J. CCK agonists and antagonists in clinical studies of panic and anxiety. Clin Neuropharm 1992;15(Suppl 1):481–482A.
12. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 1991;48:603–610.
13. Carr DB, Sheehan DV. Panic anxiety: a new biological model. J Clin Psychiatry 1984;45:323–330.
14. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984;41:751–763.
15. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233–243.
16. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and MCPP in patients and healthy subjects. Arch Gen Psychiatry 1988;45:177–185.
17. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment: I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 1985;42:458–467.
18. Charney DS, Heninger GR. Serotonin function in panic disorders: the effect of intravenous tryptophan in healthy subjects and patients with panic disorders before and during alprazolam treatment. Arch Gen Psychiatry 1986;43:1059–1065.
19. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030–1036.
20. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992;86:273–282.
21. Coplan JD, Liebowitz MR, Gorman JM, et al. Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. Biol Psychiatry 1992;31:135–146.
22. Couetoux-Dutertre A, Bradwejn J, Koszycki D, Paradis M, Bourin M. Lack of effect of flumazenil on CCK-4-panic. 1992 New Research Program and Abstracts 145th Annual Meeting, Washington, DC: American Psychiatric Association; 1992:NR138.
23. Cowley DS, Arana GW. The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:277–284.
24. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47: 411–418.
25. De Montigny C. Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Arch Gen Psychiatry 1989;46: 511–517.
26. Dunn AJ, Berridge CW. Physiological and behavioral responses in corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71–100.
27. Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992;32:457–461.
28. Goddard AW, Charney DS, Germine M, Heninger GR, Woods SW. Anxiety responses to IV MCPP in healthy subjects and patients with panic disorder. Soc Neurosci Abstr 1991;17:1456.
29. Goddard AW, Germine M, Woods SW, Delgado PL, Heninger GR, Charney DS. Effects of tryptophan depletion on anxiety responses to yohimbine in humans. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1991.
30. Goddard AW, Goodman WK, Woods SW, Heninger GR, Charney DS, Price LH. Effects of tryptophan depletion on panic anxiety. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1992.
31. Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR. Effects of the serotonin reuptake inhibitor fluvoxamine on noradrenergic function in panic disorder. Psychiatry Res 1993;48:119–133.
32. Goetz RR, Klein DF, Gully R, et al. Panic attacks during placebo procedures in the laboratory. Physiology and symptomatology. Arch Gen Psychiatry 1993;50:280–285.
33. Goodman WK, McDougle CJ, Price LH, et al. M-chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1994;[in press].
34. Gorman JM, Fyer MR, Liebowitz MR, Klein DF. Pharmacologic provocation of panic attacks. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987:985–993.
35. Gorman JM, Liebowitz MR, Fyer AJ, et al. Lactate infusions in obsessive–compulsive disorder. Am J Psychiatry 1985;142: 864–866.
36. Gorman JM, Fyer MR, Goetz R, et al. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988;45: 31–39.
37. Gorman JM, Liebowitz MR, Fyer AJ, Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 1989;146:148–161.
38. Gorman JM, Goetz RR, Dillon D, et al. Sodium D-lactate infusion in panic disorder patients. Neuropsychopharmacology 1990;3: 181–189.
39. Griez E, Lousberg H, Van den Hout MA, et al. Carbon dioxide vulnerability in panic disorder. Psychiatry Res 1987;20:87–95.
40. Gurguis GNM, Uhde TW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 1990;15:217–224.
41. Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG. Fenfluramine stimulation of prolactin in obsessive–compulsive disorder. Psychiatry Res 1992;42:81–92.
42. Hollander E, DeCaria C, Gully R, et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to metachlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1991;36:1–17.
43. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive–compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992;49: 21–28.
44. Hollander E, Liebowitz MR, DeCaria C, Klein DF. Fenfluramine, cortisol, and anxiety. Psychiatry Res 1990;31:211–213.
45. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism, and panic disorder. Horm Metab Res 1987;16(suppl):80–88.
46. Hommer DW, Skolnick P, Paul SM. The benzodiazepine/GABA receptor complex and anxiety. In: Meltzer HY, ed Psychopharmacology: the third generation of progress. New York: Raven Press; 1987:977–983.
47. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:739–744.
48. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. Damphetamine in obsessive-compulsive disorder. Psychopharmacology 1983;80:231–235.
49. Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983;140:1219–1220.
50. Joffe RT, Swinson RP. Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1987;7:420–422.
51. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:237–241.
52. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139–1166.
53. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993;50:306–317.
54. Krystal JH, Southwick SM, Morgan CA, et al. Noradrenergic and serotonergic mechanisms in PTSD. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1991.
55. Lee MA, Cameron OG, Gurguis GNM, et al. Alpha2-adrenoreceptor status in obsessive-compulsive disorder. Biol Psychiatry 1990; 27:1083–1093.
56. Lesch KP, Hoh A, Disselkamp-Tietze J, et al. 5-hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder: comparison of patients and controls. Arch Gen Psychiatry 1991;48:540–547.
57. Lesch KP, Hoh A, Schulte HM, et al. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology 1991;105:415–420.
58. Lesch KP, Wiesmann M, Hoh A, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 1992;106:111–117.
59. Lucey JV, Barry S, Webb MGT, Dinan TG. The desipramine-induced growth hormone response and the dexamethasone suppression test in obsessive–compulsive disorder. Acta Psychiatr Scand 1992;86:367–370.
60. Lucey JV, Butcher G, Clare AW, Dinan TG. Buspirone induced prolactin responses in obsessive–compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder? Int Clin Psychopharmacol 1992;7:45–49.
61. Lucey JV, Butcher G, Clare AW, Dinan TG. Elevated growth hormone responses to pyridostigmine in obsessive–compulsive disorder: evidence of cholinergic supersensitivity. Am J Psychiatry 1993;150:961–962.
62. Lucey JV, O'Keane V, Butcher G, Clare AW, Dinan TG. Cortisol and prolactin responses to D-fenfluramine in non-depressed patients with obsessive–compulsive disorder: a comparison with depressed and healthy controls. Br J Psychiatry 1992;161:517–521.
63. McBride PA, DeMeo MD, Sweeney JA, et al. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist DL-fenfluramine in adults with obsessive–compulsive disorder. Biol Psychiatry 1992;31:19–34.
64. Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber-Smith MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984;41:771–776.
65. Nutt DJ, Glue P, Lawson CW, Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:917–925.
66. Nutt D, Lawson C. Panic attacks. A neurochemical overview of models and mechanisms. Br J Psychiatry 1992;160:165–178.
67. Pigott TA, Hill JL, Grady TA, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP. Biol Psychiatry 1993;33:3–14.
68. Pitchot W, Ansseau M, Moreno AG, Hansenne M, von Frenckell R. Dopaminergic function in panic disorder: comparison with major and minor depression. Biol Psychiatry 1992;32:1004–1011.
69. Pitts FM, McClure JN. Lactate metabolism in anxiety neurosis. N Engl J Med 1967;277:1329–1336.
70. Pohl R, Yeragani VK, Balon R, et al. Isoproterenol-induced panic attacks. Biol Psychiatry 1988;24:891–902.
71. Pratt JA. The neuroanatomical basis of anxiety. Pharmacol Ther 1992;55:149–181.
72. Price LH, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in DSM-III-R depressive subtypes and healthy controls. Am J Psychiatry 1991;148:1518–1525.
73. Pyke RE, Greenberg HS. Norepinephrine challenges in panic patients. Psychopharmacol 1986;6:279–285.
74. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky D. The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry 1991;29:658–664.
75. Rapaport MH, Risch SC, Golsham S, Gillin JC. Neuroendocrine effects of ovine corticotropin-releasing hormone in panic disorder patients. Psychiatry 1989;26:344–348.
76. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky DS. Blunted growth hormone response to peripheral infusion of human growth hormone-releasing factor in patients with panic disorder. Am J Psychiatry 1989;146:92–95.
77. Rapee RM, Ancis JR, Barlow DH. Emotional reactions to physiological sensations: panic disorder patients and non-clinical Ss. Behav Res Ther 1988;26:265–269.
78. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology 1987;93:308–313.
79. Redmond DE. Studies of the nucleus locus coeruleus in monkeys and hypotheses for neuropsychopharmacology. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987:967–975.
80. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:534–538.
81. Schweizer E, Winokur A, Rickels K. Insulin-induced hypoglycemia and panic attacks. Am J Psychiatry 1986;143:654–655.
82. Siever LJ, Insel TR, Jimerson DC, et al. Growth hormone response to clonidine in obsessive-compulsive patients. Br J Psychiatry 1983;142:187–187.
83. Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:266–274.
84. Stein MB, Uhde TW. Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder. Arch Gen Psychiatry 1991;48:148–156.
85. Tancer ME, Golden RN. Monoamine neurotransmitter function in social phobia. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1992.
86. Tancer ME, Stein MB, Black B, Uhde TW. Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder. Am J Psychiatry 1993;150:336–337.
87. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Research 1989;28: 295–306.
88. Targum SD. Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 1992;17:453–458.
89. Uhde TW. Caffeine provocation of panic: a focus on biological mechanisms. In: Ballenger JC, ed. Neurobiology of panic disorder. New York: Wiley-Liss; 1990:219–242.
90. Uhde TW, Vittone BJ, Siever LJ, Kaye WH, Post RM. Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 1986;21:1077–1081.
91. Westenberg HGM, Den Boer JA. Serotonin function in panic disorder: effect of L-5-hydroxytryptophan in patients and controls. Psychopharmacology 1989;98:283–285.
92. Wilson S, Glue P, Nutt D. Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. Hum Psychopharmacol 1992;7:45–50.
93. Woods SW, Charney DS, Lake J, Goodman WK, Redmond DE, Heninger DR. Carbon dioxide sensitivity in panic anxiety: Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and panic anxiety patients before and after alprazolam treatment. Arch Gen Psychiatry 1986;43:900–909.
94. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 1991;36:115–127.
95. Woods SW, Koster K, Krystal JK, et al. Yohimbine alters regional cerebral blood flow in panic disorder. Lancet 1988;2:678.
96. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive–compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45:167–172.